P. Harris

发表

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

M. Lacouture, B. Vincenzi, G. Tonini, 2020, BMJ Open.